Kyle Doherty

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.

Adding cobolimab to dostarlimab as neoadjuvant treatment for high-risk resectable melanoma improved major pathological response rates and was tolerable.

Fruquintinib with chemotherapy and PD-1 blockade showed promising efficacy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

The SACHI trial showed savolitinib + osimertinib significantly improved PFS (8.2 vs 4.5 months) vs chemotherapy in EGFR-mutated, MET-amplified advanced NSCLC after EGFR TKI progression.

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk NMIBC with CIS. The 12-month CR rate was 45.9%, with durable responses and manageable safety. An FDA application is under review.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood cancers, per phase 1 data.

Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.

Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute lymphoblastic leukemia and those under 60.

A phase 2 trial of ipilimumab plus nivolumab has met its primary end point of 12-month overall survival rate in non-clear cell renal cell carcinoma.

The combination of benmelstobart with anlotinib led to efficacy improvements in patients with advanced renal cell carcinoma vs sunitinib.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Adding retifanlimab to carboplatin and paclitaxel improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.

Zanubrutinib with venetoclax led to an overall response rate of 100% when used for treating patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletions and/or TP53 mutations.

Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.

New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.

Zanubrutinib plus venetoclax achieved a 100% overall response rate in patients with treatment-naive CLL/SLL harboring 17p deletions and/or TP53 mutations.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.

According to findings from the phase 3 ESOPEC trial, perioperative chemotherapy given with FLOT improved overall survival in resectable esophageal cancer.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Among patients with Ph-positive chronic phase chronic myeloid leukemia, asciminib demonstrated positive results, including a better major molecular response rate at 48 weeks vs investigator-selected TKIs.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.

A study found that UGN-102, used alone or combined with TURBT, resulted in comparable duration of response and disease-free survival rates in both patients newly diagnosed with and those with recurrent low-grade/intermediate non-muscle invasive bladder cancer.

Treatment with enzalutamide alone and with leuprolide delivered higher rates of undetectable PSA levels compared with leuprolide alone in patients with castration-sensitive prostate cancer.

Treatment with TAR-200 displayed a high complete response rate in Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

An increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.

Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.

An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.